Octapharma USA, Inc. Announces FDA Approval Of Octagam 10%, Expanding Its Immune Globulin Therapy Portfolio

HOBOKEN, N.J.--(BUSINESS WIRE)--Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human) 10% (100 mg/mL) Liquid Preparation] for the treatment of adults with chronic Immune Thrombocytopenic Purpura (ITP), a platelet disorder that can result in easy or excessive bruising and bleeding.

The FDA approval marks a significant expansion of Octapharma’s U.S. immune globulin therapy portfolio. Octapharma USA is a subsidiary of Octapharma AG, a global human protein products manufacturer, and since 2004 has been marketing Octagam® 5% [Immune Globulin Intravenous (Human) 5% (50 mg/mL) Liquid Preparation] to treat Primary Humoral Immunodeficiency (PI).

Help employers find you! Check out all the jobs and post your resume.